Abstract
Nine patients with hormone-refractory metastatic prostatic adenocarcinoma and anemia were treated with recombinant human erythropoietin (rHuEpo) at a median dose of 150 U/kg BW 3 times a week subcutaneously. Baseline hemoglobin (Hb) ranged from 70 to 116 g/L, and the study duration was 12 weeks (median patient participation period was 8 weeks). Four patients demonstrated a median Hb increase of 20 g/L and were considered responders. Three patients showed a median increase of 17 g/L but required blood transfusion once, and were therefore considered as partial responders. Baseline erythropoietic status showed a significant correlation between serum Epo and Hb. Inadequate Epo production, evaluated by the observed/predicted log Epo ratio, was found in two patients. Defective bone marrow activity, demonstrated by low transferrin receptor (TfR), and hypoferremia in spite of abundant iron stores were also shown. Hemorheological investigations showed elevated plasma viscosity. Our results indicate that suppression of erythropoiesis can be mainly explained by the depressed marrow activity. The altered hemorheology might contribute to the anemia. This anemia could possibly be corrected with rHuEpo.
References
Mar 1, 1992·British Journal of Haematology·M Cazzola, Y Beguin
Oct 1, 1991·Annals of Internal Medicine·R F Schilling
Nov 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L C PlataniasM J Ratain
May 9, 1991·The New England Journal of Medicine·A J Erslev
Jan 1, 1990·Contributions to Nephrology·W JelkmannJ Fandrey
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W OsterR Mertelsmann
Jun 14, 1990·The New England Journal of Medicine·C B MillerJ L Spivak
Jun 14, 1990·The New England Journal of Medicine·H LudwigU Barnas
Jan 1, 1989·Upsala Journal of Medical Sciences·B Sandhagen
May 20, 1987·Journal of Immunological Methods·J C EgrieR C Tam
Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C Doll, R B Weiss
Jan 1, 1995·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S B Krantz
Jan 1, 1993·The Journal of Clinical Investigation·A SinghW H Reinhart
Mar 1, 1993·American Journal of Clinical Pathology·H N RaafR Green
Citations
Jan 1, 2007·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Pratipal Singh, Aneesh Srivastava
Jul 25, 2007·Clinical Genitourinary Cancer·Tomasz M BeerCelestia S Higano
Oct 30, 2004·The Journal of Laboratory and Clinical Medicine·Solo KuvibidilaWalter Rayford
Jun 11, 1999·The Urologic Clinics of North America·P Esper, B G Redman
Oct 8, 2003·The Oncologist·Carrie A ThompsonCharles L Loprinzi
Nov 18, 2003·BJU International·N W Clarke
Dec 13, 2018·Frontiers in Oncology·Driton Vela
Oct 7, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Murat O ArcasoyZishan A Haroon
Nov 1, 2000·The Prostate. Supplement·R Stege
Nov 13, 2004·The Journal of Laboratory and Clinical Medicine·Des R Richardson